Benefits
Supports Bone Mineral Density
Soy isoflavones including daidzein have been studied for bone-density support in postmenopausal women, with meta-analyses reporting modest improvements in spine BMD and reductions in bone resorption markers, particularly at doses above 75 mg/day.
May Ease Menopausal Hot Flashes
Daidzein-containing soy isoflavone preparations have been evaluated for vasomotor symptom relief during menopause. Evidence is mixed; benefits appear larger in women who are equol producers and with concentrated genistein/daidzein extracts.
Equol Producer Phenotype Matters
Approximately 25-50% of Western adults convert daidzein to S-equol via gut bacteria. Equol has greater estrogen-receptor-beta affinity, and equol producers tend to show stronger clinical responses across daidzein-mediated outcomes.
Antioxidant Phytoestrogen
Daidzein scavenges free radicals and modulates antioxidant enzyme expression in laboratory studies, contributing to soy's broader cardioprotective phytonutrient profile.
Supports Hormonal Balance Research
Daidzein's selective binding to estrogen receptor beta — implicated in bone, brain, and certain epithelial tissues — underlies ongoing interest in its role for women's hormonal health and healthy aging.
Mechanism of action
Estrogen Receptor Beta Binding
Daidzein binds ERβ with greater affinity than ERα, producing tissue-selective phytoestrogenic activity. This receptor profile distinguishes daidzein from estradiol and may explain mixed agonist/antagonist effects across tissues.
Equol Conversion by Gut Bacteria
Specific gut microbes (Slackia, Adlercreutzia, Eggerthella spp.) reduce daidzein to S-equol, a metabolite with stronger ERβ binding and longer half-life. Producer status is largely stable in adulthood and is a major source of inter-individual variability.
Bone Remodeling Modulation
Daidzein and S-equol attenuate osteoclast activity and support osteoblast function in laboratory models, providing a mechanistic basis for the bone-resorption-marker reductions seen in clinical trials.
Tyrosine Kinase Inhibition
Like genistein, daidzein has weak tyrosine kinase inhibitory activity, which may contribute to its broader effects on cellular signaling pathways beyond estrogen receptors.
Clinical trials
Systematic review and meta-analysis of randomized trials of soy isoflavone supplementation on bone mineral density and bone resorption markers in women.
Aggregated trials in pre- and postmenopausal women.
Soy isoflavone supplementation was associated with significant increases in bone mineral density and decreases in urinary deoxypyridinoline (a bone-resorption marker), with greater effects in postmenopausal women and at doses above 75 mg/day of total isoflavones.
Cochrane systematic review of 43 randomized trials (over 4,300 participants) evaluating phytoestrogen supplements including soy isoflavone preparations for hot flashes and night sweats in peri- and postmenopausal women.
Peri- and postmenopausal women with vasomotor symptoms.
No conclusive evidence overall that phytoestrogen supplements meaningfully reduce hot flash frequency or severity, though concentrated genistein-containing extracts showed promising effects warranting further investigation. Highlights heterogeneity in formulation, dose, and individual response.
6-month, parallel-group, double-blind, randomized, placebo-controlled trial of whole soy flour, purified daidzein (63 mg/day), or placebo in equol-producing Chinese postmenopausal women with prehypertension. Outcomes: menopausal symptom scales.
270 equol-producing Chinese postmenopausal women.
Whole soy and purified daidzein had no significant overall effect on menopausal symptoms versus placebo over 6 months in this equol-producing cohort, suggesting that equol-production status alone does not guarantee subjective symptom benefit.